Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
NRSN Stock Chart & Stats
$1.12
-$0.07(-5.66%)
At close: 4:00 PM EST
$1.12
-$0.07(-5.66%)
Day’s Range― - ―
52-Week Range$0.80 - $2.60
Previous CloseN/A
Volume34.16K
Average Volume (3M)944.42K
Market Cap
$29.03M
Enterprise Value$24.53M
Total Cash (Recent Filing)$666.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 26, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding24,602,406
10 Day Avg. Volume256,142
30 Day Avg. Volume944,423
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.87
Forecast
1Y Price Target
$9.00Price Target Upside703.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
ManufacturingNRSN has completed the scale-up of its manufacturing process of PrimeC to commercial scale.
Product DevelopmentNeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS), and previously received feedback from the FDA regarding the Phase trial 3 design for PrimeC.
Bears Say
Financial ConstraintsWhile the data previously generated for PrimeC has been promising, the company still has capital constraints, including its 'baby shelf' limitations, which will make it difficult to raise sufficient capital to fully finance the Phase 3 trial.
Funding UncertaintyNeuroSense still has not signed a definitive agreement with the previously-undisclosed partner to fund PrimeC’s Phase 3 program and commercialization.
Regulatory ChallengesThe company received negative feedback from Health Canada regarding an accelerated approval pathway for PrimeC for treating ALS.
Neurosense Therapeutics Ltd. News
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.80 and its highest was $2.60 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Neurosense Therapeutics Ltd.’s market cap is $29.03M.
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Nov 26, 2025 which is in 24 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Aug 01, 2025. The company reported -$0.138 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.085.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -0.06.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 24,602,406 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.138 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -40%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
Company Description
Neurosense Therapeutics Ltd.
Neurosense Therapeutics Ltd. (NRSN) is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company operates primarily in the biopharmaceutical sector, leveraging advanced scientific research and innovative technologies to create novel therapeutic solutions. Its core product candidates target conditions such as amyotrophic lateral sclerosis (ALS) and other severe neurological disorders, aiming to improve patient outcomes and quality of life.
NRSN Stock 12 Month Forecast
Average Price Target
$9.00
▲(703.57% Upside)
Technical Analysis
Tenax Therapeutics
―
Collplant Holdings
―
Kezar Life Sciences
―
Exicure
―
NeurAxis, Inc.
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.19% Other Institutional Investors
99.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---